A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 98
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SAF
Long Form : skin autofluorescence
No. Year Title Co-occurring Abbreviation
2020 Association between the tissue accumulation of advanced glycation end products and exercise capacity in cardiac rehabilitation patients. AGEs, CR, CVD, DM
2020 First-Days Reduction of Plasma and Skin Advanced Glycation End Products is Related to Outcome in Septic Patients. AGEs, PAF
2020 Impact of Dietetic Intervention on Skin Autofluorescence and Nutritional Status in Persons Receiving Dialysis: A Proof of Principle Study. AGEs, AU, HD
2020 Mediterranean diet, physical activity and subcutaneous advanced glycation end-products' accumulation: a cross-sectional analysis in the ILERVAS project. AGEs, MedDiet
2019 Advanced glycation end products are associated with sarcopenia in older women: aging marker dynamics. AGEs
2019 Advanced Glycation End Products, a Potential Link between Psoriasis and Cardiovascular Disease: A Case-control Study. AGEs, AUs, CIMT, HC, hs-CRP
2019 Comparison of skin autofluorescence, a marker of tissue advanced glycation end-products in peritoneal dialysis patients using standard and biocompatible glucose containing peritoneal dialysates. AGE, CL, PD
2019 Effects of Long-Term Physical Activity and Diet on Skin Glycation and Achilles Tendon Structure. AGEs
2019 Post-translational modification-derived products are associated with frailty status in elderly subjects. CML, Hcit, PTMDPs
10  2019 Reduced leg muscle mass and lower grip strength in women are associated with osteoporotic vertebral compression fractures. BIA, CSA, DXA, SMI, VCF
11  2019 Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational study. AGEs, CKD, CVD, ED, ESRD, LGI
12  2019 Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study. AGEs
13  2019 Skin autofluorescence in children with and without obesity. AGE, BMI-SDS
14  2019 Skin Autofluorescence Is Associated with Diabetic Peripheral Neuropathy in Chinese Patients with Type 2 Diabetes: A Cross-Sectional Study. DPN, NCS
15  2019 Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. AGEs, AU, CML, RAGE
16  2019 Skin Autofluorescence of Pregnant Women With Diabetes Predicts the Macrosomia of Their Children. AGEs, AUs, GDM
17  2019 Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Decreases During the Summer in Dialysis Patients. AGEs, HD
18  2019 Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. 1-SD, AGEs, AIx, AUC, CKD, CVD, FRS, HGS, HR, hs-CRP, ROC
19  2019 Skin autofluorescence: an emerging biomarker in persons with kidney disease. AGEs
20  2019 The Association of Nutritional Factors and Skin Autofluorescence in Persons Receiving Hemodialysis. AGEs, HD, HGS
21  2018 Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. AGEs, DCCT, HR, IQR, UKPDS
22  2018 Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant. ABI, AGEs, AU, CKD, CVD, RI, RT
23  2018 Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation endproducts (AGEs), in healthy adults. AGEs
24  2018 Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population. AGEs
25  2018 Association of skin autofluorescence with plaque vulnerability evaluated by optical coherence tomography in patients with cardiovascular disease. AGEs, CVD, LDL, OCT, PCI, TCFA
26  2018 Autofluorescence of Skin Advanced Glycation End Products as a Risk Factor for Open Angle Glaucoma: The ALIENOR Study. AGEs, AU, CI, OAG, OR, SD-OCT
27  2018 Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study. AU, BMI, MACE, T1D
28  2018 Skin Autofluorescence, as a Measure of AGE Accumulation in Individuals Suffering from Chronic Plaque Psoriasis. AGEs, CRP, ESR
29  2018 Skin autofluorescence: Correlation with measures of diabetic sensorimotor neuropathy. AGE, DPN, NDS, NSS, TCNS
30  2018 The association between skin auto-fluorescence of palmoplantar sites and microvascular complications in Asian patients with type 2 diabetes mellitus. T2DM
31  2018 The Effect of On-Line Hemodiafiltration, Vegetarian Diet, and Urine Volume on Advanced Glycosylation End Products Measured by Changes in Skin Auto-Fluorescence. AGEs, HD, HDF
32  2017 Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study. AGE, AGEs
33  2017 Advanced glycation end products as a biomarker for incisional hernia. AGEs
34  2017 Advanced glycation end-products (AGEs) accumulation in skin: relations with chronic kidney disease-mineral and bone disorder. AGEs, AGEs-sAF, CKD, CVD, iPTH
35  2017 Advanced glycation end-products in morbid obesity and after bariatric surgery: When glycemic memory starts to fail. AGEs
36  2017 Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus. AGEs, Cohens'd, CVD, DM
37  2017 Noninvasive measurement of advanced glycation end-products in the facial skin: New data for skin aging studies. AGEs
38  2017 Progression of skin autofluorescence of AGEs over 4years in patients with type 1 diabetes. CSII, eGFR
39  2017 Skin accumulation of advanced glycation end products is increased in patients with an abdominal aortic aneurysm. AAA, AGEs, CI, OR, PAD
40  2017 Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. CKD, CVD, MSM
41  2017 Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes. AGEs, AU
42  2017 Skin Autofluorescence Examination asaDiagnostic Tool for Mild Cognitive Impairment in Healthy People. AGEs, MCI, THA
43  2017 Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls - Effects of aging and endurance exercise. OU, YT, YU
44  2017 Skin autofluorescence is increased in young people with type 1 diabetes exposed to secondhand smoking. AU
45  2017 Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. MetS
46  2017 Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. AGEs
47  2017 Skin autofluorescence, renal insufficiency and retinopathy in patients with type 2 diabetes. AGEs, DR, ME, SD, T2D
48  2017 Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate. AGE, CVD, GFD, HD, ST
49  2017 The association between skin autofluorescence and mean deviation in patients with open-angle glaucoma. MD, OAG
50  2016 A novel imaging platform for non-invasive screening of abnormal glucose tolerance. AGEs
51  2016 Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus. AGEs
52  2016 Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. AGEs, BMSi, T2D
53  2016 Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease. eGFR
54  2016 Increased skin autofluorescence of children and adolescents with type 1 diabetes despite a well-controlled HbA1c: results from a cohort study. sAGEs
55  2016 Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. AGEs, AU
56  2016 Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study. AER, eGFR, MVE, T1D
57  2016 Surface Area of Detachment, Proliferative Vitreoretinopathy, and Pulse Pressure, but not AGEs, are Associated With Retinal Redetachment. AGEs, CI, OR, PVR, RRD
58  2016 The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma. cpRNFLT, MBR, MD, NTG
59  2016 The relationship between advanced glycation end products and ocular circulation in type 2 diabetes. AGEs, CMT, DR, MBR, ONH
60  2015 25-hydroxyvitamin d and advanced glycation endproducts in healthy and hypertensive subjects: are there interactions? AGEs
61  2015 A new gender-specific model for skin autofluorescence risk stratification. AGEs, AU, SR
62  2015 Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the maastricht study. AGEs
63  2015 Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population. AU
64  2015 Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. AGEs, CVD
65  2015 Is vitamin D deficiency related to accumulation of advanced glycation end products, markers of inflammation, and oxidative stress in diabetic subjects? AGE-FL, AGEs, hs-CRP, sRAGE, sVAP-1
66  2015 Relationship between cardiac tissue glycation and skin autofluorescence in patients with coronary artery disease. AGEs, CABG
67  2015 Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. AGEs, AU, DR, NDR, NPDR, PDR
68  2015 Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients. AGEs, CVD, HD, PVD
69  2015 Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis. CI, CVD, PD, SE
70  2015 Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease. CI
71  2015 Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease. ADMA, AGEs, cIMT, CKD, HD, MMP-9, PAI-1, PD, SDMA, TIMP-1
72  2015 The association between skin autofluorescence and vascular complications in Chinese patients with diabetic foot ulcer: an observational study done in Shanghai. AGEs, CHD, CVD, DFU, OR, PAD
73  2015 The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients. AGE, AU
74  2015 Type 2 diabetes, skin autofluorescence, and brain atrophy. AGEs, GMV, T2DM
75  2015 [Glycation of lens proteins in diabetes and its non-invasive assessment- first experience in the Czech Republic]. AGEs, LAF
76  2014 Advanced glycation end products in the skin are enhanced in COPD. AGEs, COPD
77  2014 Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes. AGEs
78  2014 Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years. BMI, CVD, GOAL, SCORE
79  2014 Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. MACE
80  2014 The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen. AGEs, CABG
81  2013 Advanced glycation end products assessed by skin autofluorescence: a new marker of diabetic foot ulceration. AGEs, DFU
82  2013 Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease. AGEs, BP, Ca, CKD, CVD, HD, LVMI, PD
83  2013 Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. AGEs, CI, PAD
84  2013 Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. AGE, CVE, FINDRISC, FN, FP, FPG, IGT, OGTT, Sp
85  2013 Tissue advanced glycation end product deposition after kidney transplantation. AGEs, AU, CKD
86  2013 Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment. AGEs, T2DM
87  2013 Verification of skin autofluorescence values by mass spectrometry in adolescents with type 1 diabetes: brief report. AGEs, DESI-MS
88  2012 Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy. AGEs, DM, GDM
89  2012 Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. AGEs, DM, GDM
90  2012 Factors influencing skin autofluorescence of patients with peritoneal dialysis. AGE, PD
91  2012 Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. AGEs, PAOD
92  2012 Two fluorescent wavelengths, 440(ex)/520(em) nm and 370(ex)/440(em) nm, reflect advanced glycation and oxidation end products in human skin without diabetes. AGEs, CEL, CML, em, ex, MetSO, OPs
93  2011 Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. AGEs
94  2011 Dermal factors influencing measurement of skin autofluorescence. ---
95  2011 Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. AGE, CKD, CV, CVD, RRID
96  2010 Skin autofluorescence and glycemic variability. AGEs, DM, HbA1c, IGT
97  2010 Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. AGEs, RAGEs
98  2008 Skin autofluorescence increases postprandially in human subjects. AGEs